An increased generation of oncometabolites serving as epigenetic modifiers is a key feature of cancer subtypes and cancer cell states enriched with characteristics of the epithelial-to-mesenchymal transition (EMT) program [127,128,129,130,131,132,133,134], one of the major contributors to primary and acquired resistance to PD-L1-targeted immunotherapy [135,136,137,138]. Here, CD274 is linked to cancer.